CXM Investor Presentation

8/3/2019 CXM Investor Presentation

1/46

October 25, 2011

Health Sciences& Regenerative

Medicine

InvestorPresentation


2/46

2

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Forward Looking Statements

This presentation may contain forward-looking statements, includingcomments concerning clinical trials and product development programs,evaluation of potential opportunities, the level of corporate expenditures,the assessment of Cardiums technology by potential corporate partners,capital market conditions, timing of events, cash consumption and other subjects. Actual results could differ materially from these forward-lookingstatements for many reasons, including the risks described under "RiskFactors" in the Companys Annual Report on Form 10-K and QuarterlyReports on Form 10-Q as filed with the Securities and ExchangeCommission. No guarantee about future results, performance or achievements can be made. Neither Cardium nor its agents intend toupdate any of the forward-looking statements after the date of thispresentation to conform them to actual results or to changes inexpectations.


3/46

3

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Capital-efficient business strategy focused on finding diamonds in the rough and leveraging

research and development investments by big pharma, venture and institutional investors Strategyintended to provide a diversified and more balanced portfolio of risk/return opportunities.

Excellagen Wound Care Management Platform: Initial product has now received FDA 510(k)clearance for U.S. marketing and sales Initial focus on diabetic foot ulcers Other product lineextensions currently under consideration Consistent with business strategy, support initial launch,seed the market, then monetize Now preparing for launch.

Generx Global Cardiovascular Platform: International cost-efficient Phase 3 / Registration Studynow cleared for initiation Study Design: 100 patients with SPECT imaging efficacy endpoint Initialmedical focus: Patients in Russia with advanced coronary artery disease who have limited access tocostly and rationalized bypass surgery and angioplasty / stent procedures (Russian CVD death rates5X greater than U.S.; average life expectancy for males 57 years) Preparing to initiate.

MedPodium In-House Brand Platform: Portfolio of premium, science-based, easy-to-use condition-specific nutraceuticals designed to promote personal health and well being for today's active,informed and professional lifestyles Seeking revenue-based strategic acquisitions in thenutraceutical space Preparing for initial retail launch of Nutra-Apps products in selectedgeographic areas.

Acquisition Search: Challenging economic environment continues to generate a steady stream ofdeal flow CXM remains highly selective focused primarily on late-stage clinical developmentopportunities and revenue-based businesses.

Key Investor Metrics: No outstanding debt, substantial trading liquidity, continuing news flowexpected Current capital structure provides for significant economic upside potential as CXMexecutes business strategy Capital-efficient ATM Shelf Registration in place.

Investment Highlights


4/46

4

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Company Acquisition CurrentKey Product

Portfolio ofCardiovascular Growth

Factor Biologicsfrom Schering AG

Generx [Ad5FGF-4]

Phase 3

Registration Study forInternational Markets

Endovascular

TherapeuticHypothermia System

Strategic

Sale to

DNA-ActivatedMatrices for Wound& Orthopedic Repair

Excellagen Wound CareFDA 510(k)Clearance

Preparing for InitialMarket Launch

Portfolio Status

CollateralTherapeutics

InnerCoolTherapies

Tissue RepairCompany


5/46

5

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Excellagen


6/46

6

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Excellagen: Medical Focus

ChronicDiabetic

Foot Ulcers

OtherWounds:IncludingSurgical& Burns

Pressure

Ulcers

Venous

Ulcers

FormulatedCollagen


7/46

7

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Wound Care Management PlatformFormulated Collagen Topical Gel

Highly-Refined Fibrillar Type I Bovine Collagen

Specialized Formulation

Kit Provides for up to Four Applications over 12 WeeksImmediately Following SurgicalDebridement Procedure

Pre-Formulated Ready-to-Use.One 0.5 cc Excellagen Syringe willTreat Wounds up to 5cm 2 in Size

Pre-Filled Single Use Sterile Syringes

Refrigerated Storage

For Professional Use Only


8/46

8

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Excellagen: Initial Medical Focus

Wound Care Management for Diabetic Foot Ulcers


9/46

9

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Excellagen Treatment:Diabetic Foot Ulcers

Debride Treat Bandage Offload1 2 3 4

www.excellagen.com


10/46

10

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Excellagen: Competitive Landscape

HomeTreatmentby Patient:

Regranex Topical Gel &OTC Products

MedicalDevices:

NegativePressure Wound

Therapy

Dermal / TissueEngraftment:

ProfessionalUse Standard of

Care Enhancement:Excellagen

Intregra Flowable Oasis

Dermagraft

Apligraf Graftjacket


11/46

11

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Excellagen: Strategic Fit with CurrentAdvanced Wound Healing Products

Advanced Wound Care

Treatments for Diabetic Foot Ulcers

Tissue Regeneration

Advanced Wound Healing

Professional Use

Dermal EngraftmentSpecific Therapeutic UseClaims for DFUs OnlyPrep: 24 Step Process(Requiring Documentation)Storage: Frozen (-75 C)

Higher Cost

Professional Use

Adjunct to Standard of CareSurgical DebridementBroad Product Use

ApplicationsPrep: Ready UseStorage:

Refrigeration (2

- 8

C)Lower Cost

Dermagraft is a Registered Trademark of Advanced BioHealing, a subsidiary of Shire PLC.


12/46

12

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Excellagen: Potential for Diabetic Foot Ulcer Market

Diabetic Foot Ulcers AnnualU.S. Patients with Diabetic Foot Ulcers 1

Average Number of PhysicianVisits per Year 2

Projected Patient Visits InvolvingSurgical Debridement (est. 50%)

1.3 Million

14 per patient

7 per patient

Potential Number of U.S. SurgicalDebridement Procedures for DFUs 9.1 Million

Potential Revenue Opportunity at VaryingExcellagen Market Penetration Levels 3

0.5%1.0%2.0%4.0%6.0%

8.0%10.0%

$5 Million$10 Million$20 Million$35 Million$50 Million

$70 Million$80 Million

1 American Diabetes Association.2 U.S. Department of Health and Human Services: Agency for Healthcare Research and Quality.

3 Assumes $95.00 per Excellagen Treatment.


13/46

13

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

MATRIX Clinical Study DataThe Science of Formulated Collagen Gel

Blume P, et al. Wound Repair Regen . 2011 May-Jun;19(3):302-8.

PeerReviewedMedicalJournalArticle

Formulated collagen gel causes a large and rapid time-dependent effect on tissue growth rates. A single application increases the healing rate of neuropathic DFUs..., and more frequent applications hold promise to significantly improve overall incidence of complete wound closure.


14/46

14

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

In Vitro Research Study DataThe Science of Formulated Collagen Topical Gel

Activated Platelet Release of PDGF


15/46

15

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Diabetic Foot Ulcers: Continuing Unmet Medical Need

Looking for a New Wound Care Pathway

Diabetic patients with non-healing footulcers are frustrated and disappointed withtreatment outcomes. Even with access toquality medical care and advanced woundtreatment modalities, patients in Cardiums

Matrix clinical study had unhealed footulcers averaging 69 weeks (1.3 years).


16/46

16

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Excellagen: Web-Based Banner Ad


17/46

17

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Excellagen: Web-BasedDirect-to-Consumer Positioning

Non-healing foot ulcers are serious.If you have received treatment withoutsuccess, become part of the solution,try something new! Find a new woundcare pathway with Excellagen

Find a New Wound Care Pathway


18/46

18

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Generx Late-Stage Clinical Development


19/46


20/46

20

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Cardiovascular Angiogenesis


21/46

21

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Generx Potential Economic Opportunity

Unit VolumeOpportunity per

Economic Region

Target Revenue per Dose

Level I

$2,000 / dose

Level II

$3,000 / dose

Level III

$4,000 / dose

50,000 doses $100 Million $150 Million $200 Million





22/46

22

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Generx : Historical Perspective

CollateralTherapeutics

(NASDAQ)

University of CaliforniaSan Diego

1996

Discovery, Licensingand Initial

Preclinical Studies

1997 - 2005 2005 - Present Current Status

Schering AG

Phase 1/2 toPhase 2b/3

As Strategic Partner with CollateralTherapeutics

CardiumTherapeutics

Formed toAcquire

Technology fromSchering / Bayer

FDA Phase 3 Clearancewith Fast Track Status& Phase 3 Clearancefor Registration Study

in Russia

CommercialInternationalDevelopment

Activities

RussiaBrazilIndia

Schering AcquiresCollateral in 2002

for $160 Million


23/46

23 2011 Cardium Therapeutics, Inc.

GENERX [Ad5FGF-4]

Generx [Ad5FGF-4] represents a new regenerativemedicine therapeutic class of DNA-based biologics that

is being developed for interventional cardiology that isdesigned to promote a disease-modifying physiologicalresponse which stimulates the growth of microvascular circulation based on the one-time administration, using astandard cardiac catheter, as a treatment for patientswith advanced coronary artery disease.

Generx is currently being developed for internationalmarkets outside the United States as a treatmentalternative for patients who may not have access tocostly and invasive advanced care revascularizationprocedures, including coronary artery bypass surgeryand angioplasty/stents, or may not be optimalcandidates for these procedures.


24/46

24

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Non-surgical delivery by intracoronary administration byinterventional cardiologist during an angiogram procedure

Utilizes standard balloon catheter which can be easily

integrated into diagnostic angiogram procedures or with other percutaneous coronary interventions

New induced transient ischemia / reperfusion techniques aredesigned to enhance DNA uptake and expression in the heart

40% administered to right coronary circulation and60% to left coronary circulation

Generx [Ad5FGF-4]Proprietary Intracoronary Administration of

DNA-Based Cardiovascular Growth Factor Therapeutic


25/46


26/46

26

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

DNA-Based Delivery

Angiogenic ResponseGenerx [Ad5FGF-4](alferminogene tadenovec)

Generx has been evaluated in studies of over 650 patients (including 450Generx-treated patients) in four multi-center, double-blind, placebo-controlledclinical studies at 100 medical centers. Generx is the most clinically advancedDNA-based cardiovascular angiogenic growth factor therapeutic in the world.

AGENT-2 - Representative Generx-treated patient: 77%improvement in cardiac perfusion at 8 weeks equivalentto bypass surgery and PCI (angioplasty/stenting) at one year.

One-Time Treatment

The Therapeutic Process ofCardiac Microvascular Angiogenesis

SPECT Imaging


27/46

27

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

AGENT 2: Primary Endpoint SPECT Imaging AngiogenicMechanism of Action Study

p=0.14

p


28/46


29/46


30/46

30

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Developing new andinnovative, cost-effective

advanced care for coronaryheart disease patients ininternational markets

Generx Cardio Chant


31/46

31 2011 Cardium Therapeutics, Inc.

Generx [Ad5FGF-4]Product Focus for Russian Federation

Generx is being developed to promote the growth of microvascular circulation in the heart. It is administered by a cardiologist through a cardiac catheter during an outpatient procedure.

The product is a new treatment option for patients with myocardial ischemia due to advanced coronary artery disease that have limited access to advanced medical care including coronary angioplasty and stents as well as coronary artery by-pass surgery or patients who are

not optimal candidates for those procedures.A long-term study (n = 845) has shown that patients with a higher collateral blood flow index may have an improved mortality benefit when compared to patients with a relatively lower collateral blood flow index.

Selected Health Statistics Benchmarks

Demographic Metrics UnitedStatesRussian

Federation Variance

Average Life Expectancy - Males 75 57 1 - 24%

Cardiovascular Death Rates per 100,000 (Ages 35-74) Males 2 283 1,555 5.5X

Cardiovascular Death Rates per 100,000 (Ages 35-74) Females 2 145 659 4.5X

1R I A Novosti, Feb. 2, 2010.2 American Heart Association 2009.

CONFIDENTIAL


32/46

32

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Why Generx for India?64.0 Million Indians are Projected to have

Coronary Artery Disease by 2015

Generx [Ad5FGF-4]Coronary Anatomy andCardiovascular Disease

Issues in India 1

Simpler administration and cost effective treatmentcompared to bypass and stents

First non-surgical revascularization therapy

Stimulates the growth of microvascular circulationin patients with coronary artery disease

Women and patients with more advanceddisease demonstrated significant treatmenteffect based on distal disease

New induced transient ischemiatechniques may reduce treatmentvariability in earlier stage patients

Involvement at younger age

Smaller coronary arteries

Diffuse distal disease

Multi-vessel disease

Higher incidence in women

1Source: Cardiovascular Disease Trends in India Naresh Terhan, Escorts Heart Institute and Research Centre


33/46


34/46

34

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c

.

We found a significant, gender- specific beneficial effect of

Ad5FGF-4 on total ETT time, time to

1 mm ST-segment depression, time to angina and CCS Class in women.This is the first clinical report of a gender difference in response to

cardiac angiogenic therapy.

JACCSeptember 11, 2007

The potential importance of the observed gender-specific

angiogenic response on the clinical treatment of refractory

angina is substantial and

deserves further investigation.

Generx AGENT 3 & 4

Summary Research


35/46

35

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

A well-functioning coronary collateral circulation saves lives in

patients with chronic stable coronary artery disease.

Beneficial Effects of aDisease-Induced

Angiogenic VascularizationSummary Research

From Meier et al . Circulation 2007; 116:975-83.


36/46

36

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Coronary Artery DiseaseNatural Disease-Induced Angiogenic Vascularization

ONOFF


37/46

37

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

MedPodium Initial ProductsWeb-Based Boutique

MedPodium is a portfolio of premium, science-based, easy-to-use condition-specific nutraceuticals, metabolics,aesthetics, and other products designed to promote personal health and well being based on natural formulationsfor today's active, informed and professional lifestyles. MedPodium's products address healthy lifestyle intereststhat are increasingly important in our technology-based society, including millennials (young adults aged 20 to 35)who are leading the information revolution. The MedPodiums products will feature sealed capsules, quality, easyto use pills, and will also include, fast-acting drops and sprays, and transdermal delivery system.

www.medpodium.com


38/46

38

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

MedPodium: Product Strategy

NutraceuticalFormulation

PharmaceuticalPhilosophy

X

MillennialTarget Market


39/46

39

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

MedPodium: Product Differentiation


40/46

40

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

MedPodium: Conceptual Product Focus

PositiveBrain

ChemistryModulators

MillennialTargetMarket

(Age 20 35)

Nutra Apps


41/46

41

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

Level I Level II

Sugar

Caffeine

iPod

Nutraceuticals

Nicotine

Alcohol

Medicinal Marijuana

ADHD (Ritalin )

Anxiety ( Xanax )

Depression ( Prozac, Zoloft )

Sleep ( Lunesta )

Relax ( Valium )

Pain ( Vicoden, Oxycontin )

MedPodium: Millennial Brain Chemistry Modulators


42/46

42

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

MedPodium Nutra-AppsConvenience & Retail Stores


43/46

43

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

MedPodium: Nutra AppsCommercial C-Store Positioning

Conceptual Product Inspiration


44/46

44

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

MedPodium: Nutra AppsCommercial C-Store Promotion


45/46

45

2 0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

MedPodium: Nutra AppsCommercial Strategy

Stage I

2011 2013

InitialConvenience

StoreDistribution

Program

Stage II

Broader,Product

Distribution toFood, Drug

& Mass Market


46/46

0 1 1 C a r d

i u m

T h e r a p e u

t i c s ,

I n c .

CXM Investor Presentation

Documents

Transcript of CXM Investor Presentation